[
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-24910.3322/caac.20006
]Search in Google Scholar
[
2. Jacobsen J, Pirl WF, Billings JA, Lynch TJ. Early palliative care for patients with metastatic non-small-cell lung cancer, N Engl J Med., 2010;363(8):733-74210.1056/NEJMoa1000678
]Search in Google Scholar
[
3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship., Mayo Clin Proc., 2008;83(5):584-594. doi: 10.4065/83.5.584
]Open DOISearch in Google Scholar
[
4. Simeone JC, Nordstrom BL, Patel K, Klein AB. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting., Future Oncol 2019;15(30):3491-3502. doi: 10.2217/fon-2019-0348
]Open DOISearch in Google Scholar
[
5. Bi N, Yang M, Zhang L, Chen X, Ji W, Ou G, Lin D, Wang L. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer., Clin Cancer Res. 2010 Apr 15;16(8):2383-2390. doi: 10.1158/1078-0432.CCR-09-2793
]Open DOISearch in Google Scholar
[
6. Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K. Metastatic sites and survival in lung cancer., Lung Cancer 2014;86(1):78-84. doi: 10.1016/j.lungcan.2014.07.020
]Open DOISearch in Google Scholar
[
7. Quint LE, Tummala S, Brisson LJ, Francis IR, Krupnick AS, Kazerooni EA, Iannettoni MD, Whyte RI, Orringer MB.Distribution of distant metastases from newly diagnosed non-small cell lung cancer., Ann Thorac Surg. 1996;62(1):246-250. doi: 10.1016/0003-4975(96)00220-2
]Open DOISearch in Google Scholar
[
8. Socinski MA, Morris DE, Masters GA, Lilenbaum R. American College of Chest Physicians., Chemotherapeutic management of stage IV non-small cell lung cancer., Chest. 2003 Jan;123(1 Suppl):226S-243S. doi: 10.1378/chest.123.1_suppl.226s
]Open DOISearch in Google Scholar
[
9. Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Liver metastasis at the time of initial diagnosis of lung cancer., Med Oncol., 2003;20(1):25-28. doi: 10.1385/MO:20:1:25
]Open DOISearch in Google Scholar
[
10. Sawyer TE, Bonner JA, Gould PM, Deschamps C, Lange CM, Li H. Patients with stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: implications related to the design of clinical trials., Int J Radiat Oncol Biol Phys., 1999;45(2):315-321. doi: 10.1016/s0360-3016(99)00189-3
]Open DOISearch in Google Scholar
[
11. Vidarsdottir H, Tran L, Nodin B, Jirström K, Planck M, Mattsson JSM, Botling J, Micke P, Jönsson P, Brunnström H. Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary Metastases., Am J Clin Pathol. 2018;150(6):533-544. doi: 10.1093/ajcp/aqy083
]Open DOISearch in Google Scholar
[
12. Gremel G, Bergman J, Djureinovic D, Edqvist PH, Maindad V, Bharambe BM, Khan WAZA, Navani S, Elebro J, Jirström K, Hellberg D, Uhlén M, Micke P, Pontén F. A systematic analysis of commonly used antibodies in cancer diagnostics., Histopathology.2014;64(2):293-305. doi: 10.1111/his.1225524330150
]Open DOISearch in Google Scholar
[
13. Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray., Arch Pathol Lab Med. 2012;136(2):163-171. doi: 10.5858/arpa.2011-0320-OA22288963
]Open DOISearch in Google Scholar
[
14. Xu B, Abourbih S, Sircar K, Kassouf W, Aprokian A, Tanguay S, Brimo F., Diagnostic and prognostic role of immunohistochemical expression of napsin-A aspartic peptidase in clear cell and papillary renal cell carcinoma: a study including 233 primary and metastatic cases., Appl Immunohistochem Mol Morphol. 2014;22(3):206-212. doi: 10.1097/PAI.0b013e31828ef24e23702650
]Open DOISearch in Google Scholar
[
15. Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas., Am J Clin Pathol. 2001;116(6):823-830. doi: 10.1309/21TW-2NDG-JRK4-PFJX11392877
]Open DOISearch in Google Scholar
[
16. Hoang LL, Tacha D, Bremer RE, Haas TS, Cheng L. Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma., Appl Immunohistochem Mol Morphol. 2015;23(10):711-716. doi: 10.1097/PAI.000000000000014325611245
]Open DOISearch in Google Scholar
[
17. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases., Mod Pathol. 2000;13(9):962-72. doi: 10.1038/modpathol.388017511007036
]Open DOISearch in Google Scholar
[
18. Smith RA., Manassaram-Baptiste D., Brooks D., Doroshenk M., Fedewa S., Saslow D., Brawley OW, Wender R. Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2015;65(1):30-54. doi: 10.3322/caac.2126125581023
]Open DOISearch in Google Scholar
[
19. Wang X, Adjei AA. Lung cancer and metastasis: new opportunities and challenges., Cancer Metastasis Rev 2015;34(2):169-171. doi: 10.1007/s10555-015-9562-425956388
]Open DOISearch in Google Scholar
[
20. Wao H, Mashkar R, Kumar A, Miladinovic B, Djulbegovic B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis., Syst Rev 2013;2:10. doi: 10.1186/2046-4053-2-10.357976223379753
]Open DOISearch in Google Scholar
[
21. Lu J, Zhong H, Chu T, Zhang X, Li R, Sun J, Zhong R, Yang Y, Alam MS, Lou Y, Xu J, Zhang Y, Wu J, Li X, Zhao X, Li K, Lu L, Han B. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy., Eur Respir J. 2019;53(3):1801562. doi: 10.1183/13993003.01562-201830578392
]Open DOISearch in Google Scholar
[
22. Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology., J Natl Compr Canc Netw 2017 Apr;15(4):504-53510.6004/jnccn.2017.005028404761
]Search in Google Scholar
[
23. Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl NB, Riely GJ, Schiller JH, Schneider BJ, Smith TJ, Tashbar J, Biermann WA, Masters G. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol. 2017 Oct 20;35(30):3484-3515. doi: 10.1200/JCO.2017.74.606528806116
]Open DOISearch in Google Scholar
[
24. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021, CA Cancer J Clin. 2021;71(1):7-33. doi: 10.3322/caac.2165433433946
]Open DOISearch in Google Scholar
[
25. Xiang M, Yang X, Ren S, Du H, Geng L, Yuan L, Wen Y, Lin B, Li J, Zhang Y, Feng G, Du X. Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial., Oncologist. 2021;26(12):e2130-e2135. doi: 10.1002/onco.13950864904934423518
]Open DOISearch in Google Scholar
[
26. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy., J Clin Oncol. 2015;33(17):1974-82. doi: 10.1200/JCO.2014.59.4358498057325605845
]Open DOISearch in Google Scholar
[
27. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer., J Clin Oncol. 2010;28(13):2181-2190. doi: 10.1200/JCO.2009.26.254320351327
]Open DOISearch in Google Scholar
[
28. Vinod SK, Hau E. Radiotherapy treatment for lung cancer: Current status and future directions., Respirology. 2020;25 Suppl 2:61-71. doi: 10.1111/resp.1387032516852
]Open DOISearch in Google Scholar
[
29. Delaney GP, Barton MB. Evidence-based estimates of the demand for radiotherapy., Clin Oncol (R Coll Radiol). 2015;27(2):70-6. doi: 10.1016/j.clon.2014.10.00525455408
]Open DOISearch in Google Scholar
[
30. Brown S, Banfill K, Aznar MC, Whitehurst P, Faivre Finn C. The evolving role of radiotherapy in non-small cell lung cancer., Br J Radiol. 2019;92(1104):20190524. doi: 10.1259/bjr.20190524691335931535580
]Open DOISearch in Google Scholar
[
31. Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature., Lung Cancer. 2013;82(2):197-203. doi: 10.1016/j.lungcan.2013.07.02624051084
]Open DOISearch in Google Scholar
